Your browser doesn't support javascript.
loading
Late-onset and long-lasting autoimmune neutropenia: an analysis from the Italian Neutropenia Registry.
Fioredda, Francesca; Rotulo, Gioacchino Andrea; Farruggia, Piero; Dagliano, Francesca; Pillon, Marta; Trizzino, Angela; Notarangelo, Lucia; Luti, Laura; Lanza, Tiziana; Terranova, Paola; Lanciotti, Marina; Ceccherini, Isabella; Grossi, Alice; Porretti, Laura; Verzegnassi, Federico; Mastrodicasa, Elena; Barone, Angelica; Russo, Giovanna; Bonanomi, Sonia; Boscarol, Gianluca; Finocchi, Andrea; Veltroni, Marinella; Ramenghi, Ugo; Onofrillo, Daniela; Martire, Baldassare; Ghilardi, Roberta; Giordano, Paola; Ladogana, Saverio; Marra, Nicoletta; Zanardi, Sabrina; Beier, Fabian; Miano, Maurizio; Dufour, Carlo.
Afiliação
  • Fioredda F; Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Giannina Gaslini, Genoa, Italy.
  • Rotulo GA; Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Giannina Gaslini, Genoa, Italy.
  • Farruggia P; Pediatric Hematology and Oncology Unit, ARNAS (Azienda di Rilievo Nazionale ad Alta Specializzazione) Ospedale Civico, Palermo, Italy.
  • Dagliano F; Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Giannina Gaslini, Genoa, Italy.
  • Pillon M; Pediatric Onco-Hematology Department, University of Padua, Padua, Italy.
  • Trizzino A; Pediatric Hematology and Oncology Unit, ARNAS (Azienda di Rilievo Nazionale ad Alta Specializzazione) Ospedale Civico, Palermo, Italy.
  • Notarangelo L; Oncology-Haematology and Bone Marrow Transplantation Unit, Children's Hospital Spedali Civili, Brescia, Italy.
  • Luti L; Pediatric Hematology Oncology, Bone Marrow Transplant, Azienda Ospedaliero Universitaria Pisana, S. Chiara Hospital, Pisa, Italy.
  • Lanza T; Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Giannina Gaslini, Genoa, Italy.
  • Terranova P; Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Giannina Gaslini, Genoa, Italy.
  • Lanciotti M; Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Giannina Gaslini, Genoa, Italy.
  • Ceccherini I; Medical Genetics Unit, IRCCS Giannina Gaslini Children's Hospital, Genoa, Italy.
  • Grossi A; Medical Genetics Unit, IRCCS Giannina Gaslini Children's Hospital, Genoa, Italy.
  • Porretti L; Flow Cytometry Service, Laboratory of Clinical Chemistry and Microbiology, IRCCS "Ca' Granda" Foundation, Maggiore Hospital Policlinico, Milan, Italy.
  • Verzegnassi F; Institute for Maternal and Child Health-IRCCS Burlo Garofolo, Trieste, Italy.
  • Mastrodicasa E; Pediatric Oncology Hematology Unit, S. Maria Della Misericordia Hospital, Perugia, Italy.
  • Barone A; Department of Pediatric Oncology-Hematology, University Hospital, Parma, Italy.
  • Russo G; Pediatric Hematology and Oncology Unit, Azienda Policlinico-Vittorio Emanuele, University of Catania, Catania, Italy.
  • Bonanomi S; MBBM (Monza e Brianza per Bambino e Mamma) Foundation, Department of Pediatrics, University of Milano-Bicocca, Monza, Italy.
  • Boscarol G; Department of Pediatrics, Central Teaching Hospital Bolzano, Bolzano, Italy.
  • Finocchi A; Unit of Immune and Infectious Diseases, Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Veltroni M; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Ramenghi U; Department of Pediatric Oncology-Hematology, Meyer Children's Hospital, Florence, Italy.
  • Onofrillo D; Department of Pediatric and Public Health Sciences, University of Torino, Torino, Italy.
  • Martire B; Pediatric Hematology and Oncology Unit, Department of Hematology, Spirito Santo Hospital, Pescara, Italy.
  • Ghilardi R; Unit of Pediatrics and Neonatology "Monsignor Dimiccoli" Hospital, Barletta, Italy.
  • Giordano P; Department of Pediatrics, IRCCS-Ospedale Maggiore Policlinico, Milan, Italy.
  • Ladogana S; Department of Biomedical Sciences and Human Oncology, Pediatric Section, University "A. Moro" of Bari, Bari, Italy.
  • Marra N; Pediatric Science and Surgery Department, Pediatric Oncology-Hematology Unit, Hospital Policlinico-Giovanni XXIII, Bari, Italy.
  • Zanardi S; Department of Hematology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • Beier F; AORN (Azienda Ospedaliera Rilievo Nazionale), Santobono Pausillipon, Naples, Italy.
  • Miano M; Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Giannina Gaslini, Genoa, Italy.
  • Dufour C; Biostatistic and Epidemiology Unit, IRCCS-Istituto Giannina Gaslini, Genoa, Italy; and.
Blood Adv ; 4(22): 5644-5649, 2020 11 24.
Article em En | MEDLINE | ID: mdl-33206964
ABSTRACT
Primary autoimmune neutropenia (pAN) is typified by onset in early infancy and a mild/moderate phenotype that resolves within 3 years of diagnosis. In contrast, secondary AN is classically an adult disease associated with malignancy, autoimmunity, immunodeficiency, viral infection, or drugs. This study describes a cohort of 79 children from the Italian Registry who, although resembling pAN, did not fully match the criteria for pAN because neutropenia either appeared after age 5 years (LO-Np) or lasted longer than 3 years (LL-Np). These 2 categories compared with classical pAN showed a far inferior rate of resolution (P < .001), lower severity of neutropenia (P = .03), leukopenia (P < .001), lymphopenia (P < .001) with low B+ (P = .001), increased need of granulocyte colony-stimulating factor (P = .04), and increased frequency of autoimmunity over the disease course (P < .001). A paired comparison between LO-Np and LL-Np suggested that LO-Np had a lower rate of resolution (P < .001) and lower white blood cell (P < .001) and lymphocyte (P < .001) values, higher occurrence of apthae (P = .008), and a stronger association with autoimmune diseases/markers (P = .001) than LL-Np, thus suggesting a more pronounced autoimmune signature for LO-Np. A next-generation sequencing panel applied in a small subgroup of LO-Np and LL-Np patients identified variants related to immune dysregulations. Overall, these findings indicate that there are important differences among pAN LL-Np and LO-Np. Forms rising after 3 years of age, with low tendency to resolution, require tight monitoring and extensive immune investigations aimed to early identify underlying immunologic disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Autoimunidade / Neutropenia Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Child / Child, preschool / Humans País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Autoimunidade / Neutropenia Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Child / Child, preschool / Humans País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article